Abstract: Embodiments of the present disclosure include systems and methods for determining shared exponent values for shared exponent floating point data types. A device may determine a shared global exponent value for a plurality of floating point numbers. The device may determine a sub exponent value from a plurality of candidate sub exponent values that minimizes a quantization error value determined based on a subset of the plurality of floating point numbers and a version of the subset of the plurality of floating point numbers quantized based on the shared global exponent and the sub exponent value. The determined sub exponent value is shared among the subset of the plurality of floating point numbers. The device may, based on the sub exponent value, represent the subset of the plurality of floating point numbers using a shared exponent floating point data type.

Abstract: Embodiments of the present disclosure include techniques for machine language processing. In one embodiment, the present disclosure includes configuring functional modules on a machine learning processor to execute a plurality of machine learning (ML) operations during a plurality of time segments. During the time segments, a first portion of the ML operations execute serially and at least one other ML operation executes during at least a majority of the time of each of the time segments. Serial ML operations may be processed simultaneously with the at least one other ML operation.

Abstract: The invention relates to modified release granular composition comprising melatonin and at least one non-swelling release controlling agent. The matrix granular composition as described herein may be specifically comprised of about 1 to 70% by weight of melatonin and about 10 to 70% by weight of non-swelling release controlling agent along with at least one excipient. The invention also relates to a process for preparation, wherein melatonin is uniformly embedded in at least one non-swelling release controlling agent using controlled heat conditions and the matrix granules may be optionally treated with non-swelling polymeric granulating agent to obtain modified release composition. The composition as described herein exhibits about 80% release of melatonin over 6-10 hours. The taste-masked granules can be formulated in suitable oral dosage forms which can be conveniently administered for improvement in quality of sleep to the subjects in need thereof.

Abstract: The present invention provides stabilized prolonged release pharmaceutical compositions comprising atypical antipsychotic drug like paliperidone or pharmaceutically acceptable salts thereof without incorporating surfactant and for water penetration enhancer. Such compositions are preferably in the form of a matrix wherein one or more release controlling agents are present in and/or on the matrix. Further, such compositions comprise one or more release controlling agent and exhibits desired in vitro release of drug with or without lag period. The invention also provides a process for the preparation of such compositions.

Abstract: The present invention provides stabilized prolonged release pharmaceutical compositions comprising atypical antipsychotic drug like paliperidone or pharmaceutically acceptable salts thereof without incorporating surfactant and/or water penetration enhancer. Such compositions are preferably in the form of a matrix wherein one or more release controlling agents are present in and/or on the matrix. Further, such compositions comprise one or more release controlling agent and exhibits desired in vitro release of drug with or without lag period. The invention also provides a process for the preparation of such compositions.

Abstract: A novel patient-convenient, cost effective pharmaceutical composition, comprising of thiazolidinediones and biguanide for controlling hyperglycemia manufactured as multilayer tablet and its process of manufacturing, for immediate release of thiazolidinediones or thiazolidinediones and biguanide and prolonged release of the biguanide only, the tablet comprising of minimum two layers wherein one outer layer comprises of a mixture of excipients and thiazolidinediones or thiazolidinediones and biguanide allowing immediate release of thiazolidinediones or thiazolidinediones and biguanide respectively and the other layer arranged in contact with the immediate release layer which comprises of a novel composition of excipients and a minimum one or more non-biodegradable, inert polymer(s) and the biguanide allowing pH independent prolonged release of the biguanide up to a period of 8-12 hours. The tablets are for once a day dosing.

Abstract: The present invention deals with extended release pharmaceutical compositions comprising tolterodine, wherein the composition comprises: a) a drug layer comprising tolterodine tartrate, monosaccharide and/or disaccharide on an inert core; or a drug core comprising tolterodine tartrate, monosaccharide and/or disaccharide; and b) a polymer layer comprising extended release polymer(s). The invention also provides a process for the preparation of the above mentioned composition.

Abstract: The present invention provides stabilized prolonged release pharmaceutical compositions comprising atypical antipsychotic drug like paliperidone or pharmaceutically acceptable salts thereof without incorporating surfactant and/or water penetration enhancer. Such compositions are preferably in the form of a matrix wherein one or more release controlling agents are present in and/or on the matrix. Further, such compositions comprise one or more release controlling agent and exhibits desired in vitro release of drug with or without lag period. The invention also provides a process for the preparation of such compositions.

Abstract: The present invention deals with extended release pharmaceutical composition comprising tolterodine, wherein the composition comprises of: a) a drug layer comprising of drug tolterodine tartrate, monosaccharide and/or disaccharide on an inert core; or a drug core comprising of drug tolterodine tartrate, monosaccharide and/or disaccharide; and b) a polymer layer comprising of extended release polymer(s). The invention also provides a process for the preparation of the above mentioned composition.

Abstract: The present invention provides a multiple unit compositions comprising of enteric coated pellets and at least one tablet excipient, wherein each pellet comprises: i) a core comprising active ingredient(s); ii) optionally a separating layer coated on the core; iii) at least two enteric layers comprising of enteric polymers and plasticizer either coated on the core or on the separating layer to obtain enteric coated pellets, such that the last enteric layer is formed from a solution comprising of enteric polymer and plasticizer in organic solvent(s), resulting in no appreciable change in release profile of active ingredient on compression of enteric coated pellets into tablets.

Abstract: This invention relates to a process for the manufacture of a stable, oral, multiple unit pharmaceutical composition containing high concentrations of benzimidazole up to about 35 to 45% w/w, preferably up to about 40% w/w, a disintegrating agent, and one or more fillers. Surfactants in these compositions are in an enteric polymer layer and preferably not in contact with the benzimidazole. The process preferably involves sequential deposition of: (a) an alkaline material layer on non-pariel seeds to obtain treated non-pariel seeds; (b) a drug layer of the benzimidazole to obtain drug pellets; (c) a sealant polymer layer to obtain sealed pellets; and (d) an enteric polymer layer to obtain enteric-coated pellets.